Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib

Conclusions
Our report further underlines that patients treated with Ruxolitinib should be monitored closely for reactivations of opportunistic pathogens and viral infections.

Source: BMC Hematology - July 11, 2015 Category: Hematology Source Type: research